MobiHealthNews

AliveCor gets FDA clearance for atrial fibrillation algorithm

AliveCor has received an additional FDA 510(k) clearance, this time for an algorithm that allows its smartphone ECG to detect atrial fibrillation -- an abnormal heart rhythm that isn't always ...
Nasdaq

Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023

Etripamil, an investigational drug, showed statistically significant reduction in ventricular rate by 30 beats per minute for episodes of atrial fibrillation with rapid ventricular rate (p 0.0001) ...
KRQE Blogs

Milestone Pharmaceuticals Announces Etripamil AFib-RVR Study is Selected for Featured Science Presentation at the American Heart Association Scientific Sessions 2023

MONTREAL and CHARLOTTE, N.C., Sept. 27, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that results from a double-blind, randomized, placebo-controlled Phase 2 ...
MobiHealthNews

AliveCor launches new app with FDA-cleared AFib algorithm

Smartphone-enabled heart monitor device maker AliveCor has launched a new app for patients, which is both timed with the new iOS 8 launch and incorporates the atrial fibrillation algorithm the company ...
WOOD-TV

Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023

MONTREAL and CHARLOTTE, N.C., Nov. 11, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced positive Phase 2 data that show etripamil nasal spray resulted in rapid and ...